PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17562815-0	2007	The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.	vadimezan	27-32	TANK-binding kinase 1	Mus musculus	73-77	
17562815-3	2007	Our data demonstrate that DMXAA is a novel and specific activator of the TANK-binding kinase 1 (TBK1)-interferon (IFN) regulatory factor 3 (IRF-3) signaling pathway.	vadimezan	26-31	TANK-binding kinase 1	Mus musculus	73-94	
17562815-3	2007	Our data demonstrate that DMXAA is a novel and specific activator of the TANK-binding kinase 1 (TBK1)-interferon (IFN) regulatory factor 3 (IRF-3) signaling pathway.	vadimezan	26-31	TANK-binding kinase 1	Mus musculus	96-138	
17562815-5	2007	DMXAA-induced signaling was critically dependent on the IRF-3 kinase, TBK1, and IRF-3 but was myeloid differentiation factor 88-, Toll-interleukin 1 receptor domain-containing adaptor inducing IFN-beta-, IFN promoter-stimulator 1-, and inhibitor of kappaB kinase-independent, thus excluding all known TLRs and cytosolic helicase receptors.	vadimezan	0-5	TANK-binding kinase 1	Mus musculus	70-74	
34983596-13	2022	The critical components of LGZG directly inhibited the activation of STING-TBK1-NF-kappaB pathway in liver macrophages induced by DMXAA, LPS, thereby reducing the release of IFNbeta and TNFalpha.	vadimezan	130-135	TANK-binding kinase 1	Mus musculus	75-79